Gangarapu et al. [166] found that the short-term administration of antibiotics improved clinical symptoms in NAFLD/MASH patients by lowering circulating endotoxin and IL-10 levels (0.9 ± 0.34 vs. 0.8 ± 0.13 EU/mL, p = 0.03 and 4.08 ± 0.9 vs. 3.73 ± 0.7 pg/mL, p = 0.006, respectively) as well as LFTs (AST: 50.4 ± 39 vs. 33 ± 14 IU/L, p = 0.01; ALT: 72 ± 48 vs. 45.2 ± 26.3 IU/L, p = 0.0001, GGT: 52 ± 33 vs. 41.2 ± 21.1 IU/L, p = 0.02). The gene discussed is IL10; the disease is metabolic dysfunction-associated steatotic liver disease.